This site is intended for healthcare professionals

Tepmetko is approved in Japan for the treatment of patients with unresectable, advanced or recurrent non-small cell lung cancer with MET exon 14 (METex14) skipping alterations.- Merck KGaA

Read time: 1 mins
Published:26th Mar 2020
Condition: NSCLC / MET
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest